{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:10Z","timestamp":1756425730972,"version":"3.44.0"},"reference-count":24,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:p>Travellers' diarrhoea (TD) is one of the most common illnesses to occur in people who travel overseas, and usually results from consumption of food or water contaminated with bacteria.11\u20134 Between 2004 and 2008 just over 24,000 laboratory confirmed gastrointestinal infections were reported in those who had recently travelled abroad from England, Wales and Northern Ireland. Over half the infections were caused by non-typhoidal <jats:italic>Salmonella<\/jats:italic> species (spp). As most infections are never formally diagnosed, this is believed to be a huge underestimate of the burden of TD.4 \u25bcRifaximin is a rifamycin antibacterial agent that has recently been licensed in the UK for the treatment of TD in adults. The summary of product characteristics (SPC) notes that rifaximin \u201cmay shorten the duration of diarrhoea when this is associated with non-invasive strains of E.coli\u201d.5 Here we discuss the evidence for rifaximin and how it fits in with current management strategies.<\/jats:p>","DOI":"10.1136\/dtb.2013.1.0156","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T09:07:17Z","timestamp":1357722437000},"page":"10-12","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["\u25bcRifaximin for the treatment of travellers' diarrhoea?"],"prefix":"10.1136","volume":"51","member":"239","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"2025082722243539000_51.1.10.1","doi-asserted-by":"crossref","unstructured":"Hill DR . Management of travellers' diarrhoea. BMJ 2008; 337: a1746.","DOI":"10.1136\/bmj.a1746"},{"key":"2025082722243539000_51.1.10.2","unstructured":"NHS Choices, 2011. Traveller's diarrhoea [online]. Available: http:\/\/www.nhs.uk\/Conditions\/travellersdiarrhoea\/Pages\/Introduction.aspx [Accessed 13 December 2012]."},{"key":"2025082722243539000_51.1.10.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04028.x"},{"key":"2025082722243539000_51.1.10.4","unstructured":"Health Protection Agency, 2010. Foreign travel-associated illness\u2013 a focus on travellers' diarrhoea. [online]. Available: http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1287146380314 [Accessed 13 December 2012]."},{"key":"2025082722243539000_51.1.10.5","unstructured":"Xifaxanta 200mg film coated tablets. Summary of Product Characteristics, UK. Norgine Limited, September 2011."},{"key":"2025082722243539000_51.1.10.6","doi-asserted-by":"crossref","unstructured":"Shlim DR . Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin Infect Dis 2005; 41 (suppl 8): S531\u20135.","DOI":"10.1086\/432947"},{"key":"2025082722243539000_51.1.10.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1708-8305.2008.00299.x"},{"key":"2025082722243539000_51.1.10.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1708-8305.2009.00300.x"},{"key":"2025082722243539000_51.1.10.9","doi-asserted-by":"crossref","unstructured":"de Bruyn G . Antibiotic treatment for travellers' diarrhoea. Cochrane Database Syst Rev 2000; 3: pCD002242. DOI:10.1002\/14651858.CD002241 [Last assessed as up-to-date 13 December 2012].","DOI":"10.1002\/14651858.CD002242"},{"key":"2025082722243539000_51.1.10.10","unstructured":"Health Protection Agency and British Infection Association, 2012. Management of Infection Guidance for Primary Care for Consultation and Local Adaptation [online]. Available: http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1194947333801 [Accessed 13 December 2012]."},{"key":"2025082722243539000_51.1.10.11","unstructured":"Joint Formulary Committee. British National Formulary. Edition 64. London: BMJ Group and RPS Publishing, September 2012."},{"key":"2025082722243539000_51.1.10.12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1345\/aph.1E407","article-title":"Rifaximin: a new treatment for travellers' diarrhea","volume":"39","author":"Pakyz","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2025082722243539000_51.1.10.13","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629030-00004"},{"key":"2025082722243539000_51.1.10.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00322-7"},{"key":"2025082722243539000_51.1.10.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07283.x"},{"key":"2025082722243539000_51.1.10.16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4269\/ajtmh.2006.74.1060","article-title":"A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travellers' diarrhea","volume":"74","author":"Taylor","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2025082722243539000_51.1.10.17","doi-asserted-by":"publisher","DOI":"10.1086\/323814"},{"key":"2025082722243539000_51.1.10.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.02.004"},{"key":"2025082722243539000_51.1.10.19","doi-asserted-by":"publisher","DOI":"10.1086\/591703"},{"key":"2025082722243539000_51.1.10.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04296.x"},{"key":"2025082722243539000_51.1.10.21","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549030-00009"},{"key":"2025082722243539000_51.1.10.22","unstructured":"British Medical Association, 2010. Focus on\u2026\u2026private practice [online]. Available: http:\/\/bma.org.uk\/practical-support-at-work\/private-practice [Accessed 13 December 2012]."},{"key":"2025082722243539000_51.1.10.23","unstructured":"All Wales Medicines Strategy Group, 2012. Rifaximin (Xifaxanta). Advice no: 1212\u2014June 2012 [online]. Available: http:\/\/www.wales.nhs.uk\/sites3\/Documents\/371\/Rifaximin%20(Xifaxanta)%20FAR.pdf [Accessed 13 December 2012]."},{"key":"2025082722243539000_51.1.10.24","unstructured":"Scottish Medicines Consortium, 2012. Rifaximin 200mg film coated tablets (Xifaxanta) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/808_12_rifaximin_Xifaxanta\/rifaximin_Xifaxanta [Accessed 13 December 2012]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2013.1.0156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:24:47Z","timestamp":1756358687000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2013.1.0156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,9]]},"published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1136\/dtb.2013.1.0156"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2013.1.0156","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}